S. Ekman

发表

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393

B. Eriksson, P. Close, P. Kälebo, 1996, The Lancet.

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.

P. Wille-Jørgensen, B. Eriksson, P. Close, 1997, The New England journal of medicine.

Percentage of Inadequate Phlebograms and Observer Agreement in Thromboprophylactic Multicenter Trials Using Standardized Methodology and Central Assessment

B. Eriksson, P. Close, P. Kälebo, 1996, Thrombosis and Haemostasis.

Prevention of Thromboembolism with Use of Recombinant Hirudin. Results of a Double-Blind, Multicenter Trial Comparing the Efficacy of Desirudin (Revasc) with That of Unfractionated Heparin in Patients Having a Total Hip Replacement*

B. Eriksson, P. Close, P. Kälebo, 1997, The Journal of bone and joint surgery. American volume.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

J. Laragh, A. Zanchetti, S. Kjeldsen, 2004, The Lancet.

Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).

M. Verstraete, P. Close, J. Bichler, 1994, Coronary artery disease.

DETERMINANTS OF THE NEW DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY ON TREATED HYPERTENSIVES: THE VALUE-TRIAL

R. Schmieder, S. Kjeldsen, T. Hua, 2004 .

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial

G. Mancia, A. Zanchetti, R. Schmieder, 2006, Journal of hypertension.

Direct Thrombin Inhibition with Rec-Hirudin CGP 39393 as Prophylaxis of Thromboembolie Complications after Total Hip Replacement

B. Eriksson, P. Close, P. Kälebo, 1994, Thrombosis and Haemostasis.

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

J. Laragh, A. Zanchetti, S. Kjeldsen, 2004, The Lancet.

Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial

J. Laragh, A. Zanchetti, S. Kjeldsen, 2001 .

VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk

J. Laragh, A. Zanchetti, S. Kjeldsen, 2003 .

VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk.

J. Laragh, A. Zanchetti, S. Kjeldsen, 2004, American journal of hypertension.

Cardiovascular safety of the glucagon‐like peptide‐1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta‐analysis of randomized controlled trials

J. Buse, J. Petrie, K. Ray, 2015, Diabetes, obesity & metabolism.

Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation.

J. Laragh, A. Zanchetti, S. Kjeldsen, 2001, Blood pressure.

The VALUE Trial

J. Laragh, A. Zanchetti, S. Kjeldsen, 2005 .

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

J. Laragh, A. Zanchetti, S. Kjeldsen, 2004, The Lancet.